Wells Fargo Sees Strong Upside in Tandem Diabetes After Fast Pharmacy Progress
Wells Fargo upgraded Tandem Diabetes, raising price target to $27 on strong growth, better pharmacy model, and positive outlook.
Already have an account? Sign in.